Amphastar Pharmaceuticals (AMPH) Lags Q3 Earnings and Revenue Estimates

Core Viewpoint - Amphastar Pharmaceuticals reported quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of$ 1.01 per share, and down from $1.15 per share a year ago, indicating a -4.95% earnings surprise [1] Financial Performance - The company posted revenues of$ 191.21 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 2.51%, but up from $180.56 million year-over-year [2] - Over the last four quarters, Amphastar has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times as well [2] Stock Performance - Amphastar shares have declined approximately 16.6% since the beginning of the year, contrasting with the S&P 500's gain of 21.2% [3] - The current Zacks Rank for Amphastar is 3 (Hold), indicating expected performance in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is$ 0.99 on revenues of $198.38 million, and for the current fiscal year, it is$ 4.03 on revenues of $748.75 million [7] - The estimate revisions trend for Amphastar is mixed, and future changes in estimates will be closely monitored following the recent earnings report [6][7] Industry Context - The Medical - Generic Drugs industry, to which Amphastar belongs, is currently in the top 20% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [8]